Arcturus has signed a definitive agreement to acquire myNEO

Arcturus Therapeutics (NASDAQ: ARCT, San Diego) has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions. The transaction is expected to close in October. myNEO has been working closely with Arcturus since 2024. The acquisition brings a differentiated computational engine, supported by proprietary intellectual property, intended to fortify Arcturus’ AI infrastructure by improving mRNA design quality and enhancing target identification capabilities.